CoChat
Sign Up
Cited by 287

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine

Artmann, Andreas, Petersen, Gitte, Hellgren, Lars I., Boberg, Julie, Skonberg, Christian, Nellemann, Christine, Hansen, Steen Honoré, Hansen, Harald S.·2008·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
DOI 10.1016/j.bbalip.2008.01.006
Open this paper in CoChat — free account

Abstract

Endocannabinoids and N-acylethanolamines are lipid mediators regulating a wide range of biological functions including food intake. We investigated short-term effects of feeding rats five different dietary fats (palm oil (PO), olive oil (OA), safflower oil (LA), fish oil (FO) and arachidonic acid (AA)) on tissue levels of 2-arachidonoylglycerol, anandamide, oleoylethanolamide, palmitoylethanolamide, stearoylethanolamide, linoleoylethanolamide, eicosapentaenoylethanolamide, docosahexaenoylethanolamide and tissue fatty acid composition. The LA-diet increased linoleoylethanolamide and linoleic acid in brain, jejunum and liver. The OA-diet increased brain levels of anandamide and oleoylethanolamide (not 2-arachidonoylglycerol) without changing tissue fatty acid composition. The same diet increased oleoylethanolamide in liver. All five dietary fats decreased oleoylethanolamide in jejunum without changing levels of anandamide, suggesting that dietary fat may have an orexigenic effect. The AA-diet increased anandamide and 2-arachidonoylglycerol in jejunum without effect on liver. The FO-diet decreased liver levels of all N-acylethanolamines (except eicosapentaenoylethanolamide and docosahexaenoylethanolamide) with similar changes in precursor lipids. The AA-diet and FO-diet had no effect on N-acylethanolamines, endocannabinoids or precursor lipids in brain. All N-acylethanolamines activated PPAR-alpha. In conclusion, short-term feeding of diets resembling human diets (Mediterranean…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bbalip.2008.01.006

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 74

  1. Devane, 1992, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, 258, 1946, 10.1126/science.1470919 · DOI · Paper page
  2. Mechoulam, 1995, Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochem. Pharmacol., 50, 83, 10.1016/0006-2952(95)00109-D · DOI · Paper page
  3. Kondo, 1998, Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis, Arch. Biochem. Biophys., 354, 303, 10.1006/abbi.1998.0688 · DOI
  4. Bisogno, 1999, Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina, Arch. Biochem. Biophys., 370, 300, 10.1006/abbi.1999.1410 · DOI
  5. Hansen, 2001, Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death, J. Neurochem., 76, 39, 10.1046/j.1471-4159.2001.00006.x · DOI
  6. Di Marzo, 1994, Formation and inactivation of endogenous cannabinoid anandamide in central neurons, Nature, 372, 686, 10.1038/372686a0 · DOI
  7. Schmid, 1990, N-acylated glycerophospholipids and their derivatives, Prog. Lipid Res., 29, 1, 10.1016/0163-7827(90)90004-5 · DOI
  8. Hansen, 2000, N-acylethanolamines and precursor phospholipids — relation to cell injury, Chem. Phys. Lipids, 108, 135, 10.1016/S0009-3084(00)00192-4 · DOI
  9. Okamoto, 2004, Molecular characterization of a phospholipase D generating anandamide and its congeners, J. Biol. Chem., 279, 5298, 10.1074/jbc.M306642200 · DOI
  10. Sun, 2004, Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D, Biochem. J., 380, 749, 10.1042/bj20040031 · DOI
  11. Liu, 2006, A biosynthetic pathway for anandamide, Proc. Natl. Acad. Sci. U. S. A., 103, 13345, 10.1073/pnas.0601832103 · DOI
  12. Leung, 2006, Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids, Biochemistry, 45, 4720, 10.1021/bi060163l · DOI
  13. Simon, 2006, Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway, J. Biol. Chem., 281, 26465, 10.1074/jbc.M604660200 · DOI
  14. Sugiura, 2006, Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, Prog. Lipid Res., 45, 405, 10.1016/j.plipres.2006.03.003 · DOI
  15. Sugiura, 2002, Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance, Prostaglandins Leukot. Essent. Fatty Acids, 66, 173, 10.1054/plef.2001.0356 · DOI
  16. Ueda, 1998, A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors, J. Med. Invest., 45, 27
  17. Di Marzo, 1998, The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide, Biochem. J., 331, 15, 10.1042/bj3310015 · DOI
  18. Gonzalez, 1999, Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland, Neuroendocrinology, 70, 137, 10.1159/000054468 · DOI
  19. Robbe, 2002, Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens, Proc. Natl. Acad. Sci. U. S. A., 99, 8384, 10.1073/pnas.122149199 · DOI
  20. Burdyga, 2004, Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin, J. Neurosci., 24, 2708, 10.1523/JNEUROSCI.5404-03.2004 · DOI
  21. Partosoedarso, 2003, Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets, J. Physiol., 550, 149, 10.1113/jphysiol.2003.042242 · DOI
  22. Osei-Hyiaman, 2005, Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity, J. Clin. Invest., 115, 1298, 10.1172/JCI200523057 · DOI
  23. Matias, 2006, Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia, J. Clin. Endocrinol. Metab., 91, 3171, 10.1210/jc.2005-2679 · DOI
  24. Bluher, 2006, Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity, Diabetes, 55, 3053, 10.2337/db06-0812 · DOI
  25. Juan-Pico, 2006, Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell, Cell Calcium, 39, 155, 10.1016/j.ceca.2005.10.005 · DOI
  26. Coutts, 2004, The gastrointestinal pharmacology of cannabinoids: an update, Curr. Opin. Pharmacol., 4, 572, 10.1016/j.coph.2004.05.007 · DOI
  27. Pinto, 2002, Endocannabinoids and the gut, Prostaglandins Leukot. Essent. Fatty Acids, 66, 333, 10.1054/plef.2001.0345 · DOI
  28. Williams, 1999, Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors, Psychopharmacology (Berl), 143, 315, 10.1007/s002130050953 · DOI
  29. Kirkham, 2002, Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol, Br. J. Pharmacol., 136, 550, 10.1038/sj.bjp.0704767 · DOI · Paper page
  30. Gomez, 2002, A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding, J. Neurosci., 22, 9612, 10.1523/JNEUROSCI.22-21-09612.2002 · DOI
  31. Izzo, 2001, The gastrointestinal pharmacology of cannabinoids, Curr. Opin. Pharmacol., 1, 597, 10.1016/S1471-4892(01)00102-3 · DOI
  32. Hornby, 2004, Involvement of cannabinoid receptors in gut motility and visceral perception, Br. J. Pharmacol., 141, 1335, 10.1038/sj.bjp.0705783 · DOI
  33. Ravinet, 2004, CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity, Int. J. Obes. Relat. Metab. Disord., 28, 640, 10.1038/sj.ijo.0802583 · DOI
  34. Navarro, 2001, An anorexic lipid mediator regulated by feeding, Nature, 414, 209, 10.1038/35102582 · DOI
  35. Fu, 2006, Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine, J. Biol. Chem., 282, 1518, 10.1074/jbc.M607809200 · DOI
  36. Nielsen, 2004, Food intake is inhibited by oral oleoylethanolamide, J. Lipid Res., 45, 1027, 10.1194/jlr.C300008-JLR200 · DOI
  37. Oveisi, 2004, Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration, Pharmacol. Res., 49, 461, 10.1016/j.phrs.2003.12.006 · DOI
  38. Fu, 2003, Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha, Nature, 425, 90, 10.1038/nature01921 · DOI
  39. Fu, 2005, Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats, Neuropharmacology, 48, 1147, 10.1016/j.neuropharm.2005.02.013 · DOI
  40. Guzman, 2004, Oleoylethanolamide stimulates lipolysis by activating the nucelar receptor PPAR-alpha, J. Biol. Chem., 279, 27849, 10.1074/jbc.M404087200 · DOI · Paper page
  41. Yang, 2007, Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction, Am. J. Physiol., Regul. Integr. Comp. Physiol., 292, R235, 10.1152/ajpregu.00270.2006 · DOI
  42. Lo Verme, 2005, The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide, Mol. Pharmacol., 67, 15, 10.1124/mol.104.006353 · DOI · Paper page
  43. Sun, 2006, Cannabinoids and PPARalpha signalling, Biochem. Soc. Trans., 34, 1095, 10.1042/BST0341095 · DOI
  44. Matias, 2007, Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells, Br. J. Pharmacol., 152, 676, 10.1038/sj.bjp.0707424 · DOI
  45. Overton, 2006, Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents, Cell Metab., 3, 167, 10.1016/j.cmet.2006.02.004 · DOI
  46. Soga, 2005, Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor, Biochem. Biophys. Res. Commun., 326, 744, 10.1016/j.bbrc.2004.11.120 · DOI
  47. Sakamoto, 2006, Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells, Biochem. Biophys. Res. Commun., 351, 474, 10.1016/j.bbrc.2006.10.076 · DOI
  48. Chu, 2007, A role for {beta}-cell-expressed GPR119 in glycemic control by enhancing glucose-dependent insulin release, Endocrinology, 148, 2601, 10.1210/en.2006-1608 · DOI
  49. Terrazzino, 2004, Stearoylethanolamide exerts anorexic effects in mice via down-regulation of liver stearoyl-coenzyme A desaturase-1 mRNA expression, FASEB J., 18, 1580, 10.1096/fj.03-1080fje · DOI
  50. Movahed, 2005, Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists, J. Biol. Chem., 280, 38496, 10.1074/jbc.M507429200 · DOI
  51. Zygmunt, 1999, Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide, Nature, 400, 452, 10.1038/22761 · DOI · Paper page
  52. Smart, 2000, The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1), Br. J. Pharmacol., 129, 227, 10.1038/sj.bjp.0703050 · DOI · Paper page
  53. Suardiaz, 2007, Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain, Pain, 133, 99, 10.1016/j.pain.2007.03.008 · DOI
  54. Elmes, 2005, Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat, Pain, 118, 327, 10.1016/j.pain.2005.09.005 · DOI · Paper page
  55. Jayamanne, 2006, Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models, Br. J. Pharmacol., 147, 281, 10.1038/sj.bjp.0706510 · DOI · Paper page
  56. Scott, 2004, Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat, Pain, 109, 124, 10.1016/j.pain.2004.01.020 · DOI
  57. Petersen, 2006, Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors, Biochim. Biophys. Acta, 1761, 143, 10.1016/j.bbalip.2005.12.011 · DOI
  58. Berger, 2001, Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets, Proc. Natl. Acad. Sci. U. S. A., 98, 6402, 10.1073/pnas.101119098 · DOI
  59. Watanabe, 2003, n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice, Prostaglandins Leukot. Essent. Fatty Acids, 69, 51, 10.1016/S0952-3278(03)00056-5 · DOI
  60. Kingsley, 2003, Analysis of endocannabinoids by Ag+ coordination tandem mass spectrometry, Anal. Biochem., 314, 8, 10.1016/S0003-2697(02)00643-7 · DOI
  61. Giuffrida, 2000, Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry, Anal. Biochem., 280, 87, 10.1006/abio.2000.4509 · DOI
  62. Folch, 1957, A simple method for the isolation and purification of total lipides from animal tissues, J. Biol. Chem., 226, 497, 10.1016/S0021-9258(18)64849-5 · DOI · Paper page
  63. Ma, 2007, Altered brain lipid composition in cyclooxygenase-2 knockout mouse, J. Lipid Res., 48, 848, 10.1194/jlr.M600400-JLR200 · DOI
  64. Hansen, 2006, Endocannabinoids, Eur. J. Lipid Sci. Technol., 108, 877, 10.1002/ejlt.200600157 · DOI
  65. Sugiura, 2006, Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, Prog. Lipid Res., 45, 405, 10.1016/j.plipres.2006.03.003 · DOI
  66. Lauritzen, 2001, The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina, Prog. Lipid Res., 40, 1, 10.1016/S0163-7827(00)00017-5 · DOI
  67. Bourre, 1992, Dietary α-linolenic acid deficiency in adult rats for 7 months does not alter brain docosahexaenoic acid content, in contrast to liver, heart and testes, Biochim. Biophys. Acta: Lipids and Lipid Metabol., 1124, 119, 10.1016/0005-2760(92)90087-C · DOI
  68. Hulbert, 2003, Life, death and membrane bilayers, J. Exp. Biol., 206, 2303, 10.1242/jeb.00399 · DOI
  69. Osei-Hyiaman, 2005, Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity, J. Clin. Invest., 115, 1298, 10.1172/JCI200523057 · DOI
  70. Sugiura, 1999, Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor — structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds, J. Biol. Chem., 274, 2794, 10.1074/jbc.274.5.2794 · DOI
  71. Hulshof, 1999, Intake of fatty acids in western Europe with emphasis on trans fatty acids: the TRANSFAIR study, Eur. J. Clin. Nutr., 53, 143, 10.1038/sj.ejcn.1600692 · DOI
  72. Kim, 2003, Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis, Diabetes, 52, 1770, 10.2337/diabetes.52.7.1770 · DOI
  73. Yang, 2007, Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction, Am. J. Physiol. Regul. Integr. Comp. Physiol, 292, R235, 10.1152/ajpregu.00270.2006 · DOI
  74. Wang, 2005, Oleoylethanolamide excites vagal sensory neurons, induces viceral pain and reduces food intake via TRPV1, J. Physiol.(Lond.), 564, 541, 10.1113/jphysiol.2004.081844 · DOI

Cited by

Sorted by citations

Metadata

Authors
Artmann, A., Petersen, G., Hellgren, L. I., Boberg, J., Skonberg, C., Nellemann, C., Hansen, S. H., & Hansen, H. S.
Venue
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Publisher
Elsevier BV
Published
2008-04
Volume
1781
Issue
4
Pages
200-212
ISSN
1388-1981
DOI
10.1016/j.bbalip.2008.01.006
Cited by
287
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review